Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02159755 · ClinicalTrials.gov registry record · Phase 1
Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
A Phase 1 study of Recurrent Mantle Cell Lymphoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 4
- Study locations
NCT02159755 is a Phase 1 study of Recurrent Mantle Cell Lymphoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 28 participants, below the 37-participant average among 27 other Recurrent Mantle Cell Lymphoma trials with a reported enrollment target (24% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02159755, a Phase 1 study of Recurrent Mantle Cell Lymphoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of ibrutinib and palbociclib in treating patients with previously treated mantle cell lymphoma. Ibrutinib and palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Palbociclib may also help ibrutinib work better by making cancer cells more sensitive to the drug.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Palbociclib
- DRUG Ibrutinib
- OTHER Pharmacological Study
Study Locations (4)
Missouri
- Washington University School of Medicine - St Louis
New York
- NYP/Weill Cornell Medical Center - New York
North Carolina
- UNC Lineberger Comprehensive Cancer Center - Chapel Hill
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2014-08-13 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02159755
The ClinicalTrials.gov registry entry for NCT02159755 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 37-participant average among 27 other Recurrent Mantle Cell Lymphoma trials with a reported enrollment target (24% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Mantle Cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02159755 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Missouri, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02159755 about?
NCT02159755 is a clinical study titled "Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma". This phase I trial studies the side effects and best dose of ibrutinib and palbociclib in treating patients with previously treated mantle cell lymphoma. Ibrutinib and palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Palbociclib may also help ib...
What is the current status of trial NCT02159755?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2014-08-13. Estimated completion is 2026-12-01.
What conditions does trial NCT02159755 study?
This clinical trial studies the following conditions: Recurrent Mantle Cell Lymphoma.
What interventions are being tested in trial NCT02159755?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Palbociclib (DRUG), Ibrutinib (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02159755?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02159755 being conducted?
This trial has 4 study locations across Missouri, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Mantle Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
RECRUITING · Phase 1
-
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
RECRUITING · Phase 1
-
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.